admin – Page 5172 – Get News Story

Medical Equipment Maintenance Market: Forecasted USD 88.9 Billion by 2029, CAGR 10.5%

“Some of the major players operating in the medical supplies market are Medtronic plc (Ireland), Cardinal Health (US), BD (US), Johnson & Johnson, Inc. (US), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (US), Thermo Fisher Scientific, Inc. (US), Baxter (US), 3M (US), Smith & Nephew (Ireland)”

The global medical supplies market in terms of revenue was estimated to be worth $138.4 billion in 2022 and is poised to reach $163.5 billion by 2027

Projected to grow at a CAGR of 10.5%, the global medical equipment maintenance market is anticipated to reach USD 88.9 billion by 2029, up from USD 54.0 billion in 2024. This growth is fueled by the escalating prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer, driving up the demand for essential medical devices. Healthcare facilities are increasingly investing in advanced equipment to ensure accurate diagnosis, treatment, and monitoring, necessitating regular maintenance to uphold optimal functionality and reliability. However, the significant initial costs of acquiring medical equipment, coupled with ongoing budget constraints in healthcare facilities, pose challenges, prompting providers to seek cost-effective maintenance solutions. Key players like GE Healthcare Technologies Inc., Siemens Healthineers, and Medtronic plc offer comprehensive maintenance services tailored to meet the diverse needs of healthcare facilities globally, ensuring operational excellence and patient safety.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=69695102

Industry Dynamics: Growth Drivers in Medical Equipment Maintenance

Growth in Medical Equipment Markets: The global expansion of various medical equipment markets is fueled by the need for safer, more efficient, and higher-quality healthcare. Innovations in the sector further drive this growth, with patients increasingly favoring technologically advanced devices due to improved affordability and accessibility. Distribution channels, including e-commerce platforms and third-party providers, contribute to this growth, facilitated by expanded delivery infrastructure and comprehensive networks.

Restraints: High Initial Costs and Maintenance Expenditure

High Initial Costs and Maintenance Expenditure: Maintenance programs for medical devices are crucial for effective utilization and uptime tracking, especially amid austerity measures. These programs often incorporate asset management solutions leveraging advanced technologies. However, substantial installation and ongoing maintenance expenses hinder adoption. Annual service contract fees, approximately 12% of equipment costs, and cumulative service costs exceeding purchase prices deter many end users from adopting advanced technologies.

Opportunity: Emergence of Independent Service Organizations (ISOs)

Emergence of Independent Service Organizations: Independent Service Organizations (ISOs) are rising, offering maintenance services that OEMs may lack in efficiency and satisfaction. ISOs service multiple device brands, providing centralized management platforms and significantly reducing maintenance costs. With ISOs charging 30-50% less than OEMs for maintenance and repairs, they become increasingly preferred by end users, offering flexible contracts and shorter response times.

Challenge: Survival of Small Players in a Competitive Market

Survival of Small Players: The highly fragmented and competitive medical equipment maintenance market poses challenges for smaller players, including startups and local entities, in sustaining their presence. Substantial capital requirements, logistical challenges, and regulatory hurdles make survival difficult. Larger companies focus on technology development, acquisitions, and partnerships, creating a competitive environment where cost becomes crucial for end users.

Market Ecosystem

Leading players like Siemens Healthineers, GE Healthcare Technologies Inc., Medtronic plc, Koninklijke Philips N.V., and FUJIFILM Holdings Corporation dominate the medical equipment maintenance market with diversified portfolios, advanced technologies, and global presence, shaping the industry landscape significantly.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=69695102

Diagnostic Imaging Equipment Leads Medical Equipment Maintenance Market

Segmented by device type, the medical equipment maintenance market covers various categories, including diagnostic imaging equipment, surgical equipment, dental equipment, and more. Notably, in 2023, the diagnostic imaging equipment segment held the largest market share. The rapid technological evolution in this sector necessitates frequent upgrades, driving demand for maintenance services. Staying current with technological advancements is crucial for healthcare facilities to maintain competitiveness and efficacy, prompting investments in maintenance to optimize equipment performance and deliver enhanced diagnostic capabilities.

Multi-Vendor OEMs Dominate Maintenance Services

Segmented by service provider, the market includes multi-vendor OEMs, single-vendor OEMs, ISOS, and in-house maintenance. Multi-vendor OEMs command the largest share, offering customized maintenance solutions tailored to the unique requirements and financial constraints of healthcare institutions. This tailored approach enhances operational efficiency and cost-effectiveness while ensuring the reliability and longevity of critical medical equipment.

Preventive Maintenance Foreseen for Substantial Growth

Segmented by service type, the market comprises operational, corrective, and preventive maintenance. The preventive maintenance segment is expected to witness significant growth due to its proactive benefits. By implementing preventive maintenance protocols, healthcare facilities cultivate continuous improvement, enhancing operational efficiency, minimizing downtime, and sustaining the reliability and performance of critical medical equipment assets.

Hospitals Lead End User Segment

Segmented by end users, hospitals account for the largest share, actively involved in improving operational efficiency and patient care quality. Maintenance services play a crucial role in ensuring the dependability, effectiveness, and durability of medical equipment assets, contributing to seamless healthcare delivery and enhanced patient outcomes and satisfaction.

Premium Contracts Dominate Contract Types

Segmented by contract type, premium contracts hold the largest share, offering customizable pricing models and flexible payment terms tailored to facility budgetary constraints. This bespoke approach ensures maintenance services remain accessible while optimizing cost-effectiveness and operational efficiency.

Asia Pacific Emerges as Fastest-Growing Market

The Asia Pacific region is estimated to be the fastest-growing market, driven by government healthcare reforms, investments in maintenance infrastructure, and increasing demand for high-quality healthcare services. The influx of medical tourists further boosts demand for well-maintained medical equipment in hospitals and medical centers, driving market growth in the region.

Recent Developments in Medical Equipment Maintenance:

In October 2023, GE Healthcare partnered with reLink Medical to offer asset management solutions, aiding healthcare providers in reducing medical device waste, enhancing operational efficiency, and maximizing equipment utilization. This collaboration aims to optimize resources by assisting in managing end-of-life medical equipment effectively.
May 2023 witnessed Siemens Healthineers and CommonSpirit Health acquiring Block Imaging to provide sustainable options and meet the increasing demand for multi-vendor imaging parts and services in the U.S. hospitals, health systems, and other care sites.
April 2023 saw Koninklijke Philips collaborating with Amazon Web Services (AWS) to develop and deploy generative AI applications. This partnership offers migration expertise, cost analysis, and cybersecurity technical support for customers transitioning from on-premises to cloud-based solutions, facilitating seamless integration and deployment.

For more information, inquire now! Inquire Now

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/medical-equipment-maintenance-market-69695102.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Medical Equipment Maintenance Market: Forecasted USD 88.9 Billion by 2029, CAGR 10.5%

Exosomes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Exosomes Pipeline Insight 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Exosomes Pipeline. Dive into DelveInsight’s comprehensive report today! @ Exosomes Pipeline Outlook

Key Takeaways from the Exosomes Pipeline Report

In August 2024:- Ablon Skin Institute Research Center- The goal of this clinical trial is to further substantiate the effectiveness and safety of BENEV Exosome Regenerative Complex+ post SylFirmX® RF microneedling procedure for self-perceived thinning hair in healthy men and women ages 18-65 over the course of four months. Participants will be asked to have treatments monthly for 4 sessions, attend a follow up appointment 4 weeks after the 4th session, have photos taken of their hair and answer questionnaires related to their thinning hair.
DelveInsight’s Exosomes pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Exosomes treatment.
The leading Exosomes Companies such as Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, and Direct Biologics, and others.
Promsiing Exosomes therapies such as Anlotinib, AGLE 102, TISSEEL, and others.

Stay ahead with the most recent pipeline outlook for Exosomes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Exosomes Treatment Drugs

Exosomes Emerging Drugs

CAP-1002: Capricor

Capricor’s (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. CAP-1002 contains cardiosphere-derived cells, a type of heart cell progenitor, or precursor cell, that secretes tiny vesicles called exosomes. These exosomes then modulate the activity of the immune system and stimulate cellular regeneration. It is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair. Currently, the drug is in Phase III stage of its development for the treatment of Duchenne Muscular Dystrophy.

Progenza: Regeneus

Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing. Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue. Adipose derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types. The MSCs are expanded through the company’s proprietary and scalable manufacturing process. The company has demonstrated the capacity to produce millions of therapeutic doses of Progenza from a single donor. When Progenza cells are injected into the damaged joint or tissue, the MSCs have the potential to reduce pain and inflammation and slow the progression of disease. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Osteoarthritis.

AGLE 102: Aegle Therapeutics

AGLE-102 contains COL7 protein as well as COL7A1 mRNA, which in preclinical models stimulates recessive DEB cells (cannot make any COL7) to produce COL7. AGLE-102 has the potential to induce functional regeneration and organization of complex tissue structures in DEB and EB patients that can potentially accelerate and enhance healing, reduce scarring, and improve overall cosmesis. In addition, AGLE-102 is non-immunogenic and carries the immunomodulating and anti-inflammatory properties of MSCs. Aegle’s Phase I/II clinical trial involving AGLE-102 in individuals living with Recessive Dystrophic Epidermolysis Bullosa (RDEB) is now open for enrollment. Currently, the drug is in Phase I/II stage of its development for the treatment of Dystrophic Epidermolysis Bullosa.

Explore groundbreaking therapies and clinical trials in the Exosomes Pipeline. Access DelveInsight’s detailed report now! @ New Exosomes Drugs

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Exosomes Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Exosomes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Exosomes Market Drivers and Barriers

Scope of the Exosomes Pipeline Report

Coverage- Global
Exosomes Companies- Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, and Direct Biologics, and others.
Exosomes therapies- Anlotinib, AGLE 102, TISSEEL, and others.
Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Exosomes Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Exosomes Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Exosomes : Overview
Pipeline Therapeutics
Therapeutic Assessment
Exosomes – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
CAP-1002: Capricor Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Progenza: Regeneus
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
AGLE 102: Aegle Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Exosomes Key Companies
Exosomes Key Products
Exosomes – Unmet Needs
Exosomes – Market Drivers and Barriers
Exosomes – Future Perspectives and Conclusion
Exosomes Analyst Views
Exosomes Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exosomes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

AI Governance Market Growing Trends, Business Growth, Size, Future Scope, Segmentation, Dynamics and Forecast to 2029

“Microsoft (US), IBM (US), SAS Institute (US), DataRobot (UK), and Dataiku (US), along with SMEs and startups such as Fiddler AI (US), 2021.AI (Denmark), Monitaur (US), Credo AI (US).”

AI Governance Market by Functionality (Model Lifecycle Management, Risk & Compliance, Monitoring & Auditing, Ethics & Responsible AI), Product Type (End-to-end AI Governance Platforms, MLOps & LLMOps Tools, Data Privacy Tools) – Global Forecast to 2029.

The global AI governance market is projected to grow at a compound annual growth rate (CAGR) of 45.3% during the forecast period, increasing from an estimated USD 890.6 million in 2024 to USD 5,776.0 million by 2029. This growth is largely driven by rising regulatory compliance pressures encouraging organizations to implement governance frameworks, heightened awareness of risk mitigation leading to greater investment in AI governance tools, increased adoption of AI governance in regulated industries, and growing demand for trust and transparency within the AI governance market.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=176187291

Regulatory pressure and demands for compliance are driving the AI governance market as governments around the world roll out tougher regulations related to AI. For example, the European Union’s AI Act had subjected risk assessments and compliance audits to AI systems, particularly in high-risk sectors like health and finance, thereby increasing demand for the governance framework. Organizations also run the risk of facing reputational damages linked with prejudiced or harmful AI output. A notable example is the controversy caused by OpenAI GPT models, which flagged misinformation and biased data concerns, making businesses adopt robust AI guard rails. On similar note, Amazon’s discontinuation of its biased AI recruiting tool demonstrate the reputational and financial risks of ungoverned AI. Another major reason for market expansion is the uptick in AI adoption across highly regulated industries, especially BFSI and healthcare. Industries operating in these sectors are under immense regulatory pressure to comply with dynamic regulations, leading to increased affinity towards AI governance tools.

By product type, data governance tools will account for largest market share in 2024 owing to robust data provenance and lineage capabilities.

Data governance tools are poised to account for the largest market share in the AI governance market, as these tools help an organization track data quality, provenance, and bias within AI development training data. This is important in order to prevent bias results being generated from AI systems. For example, data governance tools may apply profiling techniques to the dataset in order to ensure fairness, and also put in place data lineage to indicate potential problems with data sourcing. As an increasing number of AI regulations call for documentation, tracking and record keeping especially on the data that feeds AI systems, data governance has become paramount. Data governance also assists enterprises in compliance with regulations through robust AI data traceability and accuracy. Additionally, the metadata repository feature in data governance tools offer centralized catalogs and controls of metadata for data visibility across an organization to ensure trustworthy and responsible AI implementation.

The demand for ethical AI use across ML platforms and generative AI models will push software & technology providers as the fastest growing end user segment during the forecast period

Software & technology providers are poised to become the fastest growing end user segment in the AI governance market, buoyed by rapid adoption of AI governance tools to make their AI systems trustworthy and ethical. The rising regulatory scrutiny and the expanding reach of data privacy laws like GDPR and CCPA has also accelerated governance frameworks being adopted across such players. For instance, Microsoft has created an internal AI ethics working group to implement strong ethical guardrails across its AI offerings. On a similar note, Google has formed AI governance framework for developing fair, explainable, and ethical AI solutions. There are also expectations from stakeholders who demand that technology companies create AI responsibly. With AI regulations likely to disrupt every software vendor, incorporating ethical norms and regulation is now of extraordinary importance for technology businesses to maintain the brand’s trust and growth.

North America is set to hold the largest market share in 2024, fueled by a strong regulatory environment and increasing investments in responsible AI deployment

North America has emerged as the largest regional market for AI government adoption. Federal funding on AI governance in North America crossed USD 1 billion in 2023, indicating a growing interest in responsible AI research. Industries with strict regulations such as healthcare and banking are leading in the implementation of governance, with 45% of healthcare providers mentioning regulatory compliance as a key business requirement. Businesses are forced to implement governance frameworks due to rising regulatory requirements like NIST’s AI Risk Management Framework and the California Consumer Privacy Act (CCPA). More than half of businesses expect more stringent AI rules in the next five years, with 62% citing data privacy compliance as a main factor for implementing governance. Also important is consumer confidence, as 78% of American consumers favor brands that utilize ethical AI. Businesses such as Google and Microsoft are implementing governance to guarantee transparency and establish trust. Additionally, organizations are prioritizing fairness in their AI systems and have turned to tools like IBM’s AI Fairness 360 to address the need to mitigate AI bias, with 56% of businesses doing so. Moreover, financial institutions are particularly focused on risk management, giving priority to governance for addressing AI-related risks.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=176187291

Unique Features in the AI Governance Market

Regulatory pressures are a significant force shaping the AI governance landscape. Governments and regulatory bodies worldwide are enacting policies and laws to ensure responsible AI usage, which has prompted organizations to adopt AI governance frameworks.

Organizations are increasingly aware of the risks associated with AI, such as bias, data privacy concerns, and unintended consequences. This heightened awareness has led to a surge in investment in AI governance tools that help mitigate these risks. These tools ensure that AI systems are transparent, accountable, and designed to minimize negative outcomes, making risk management a crucial differentiator in the market.

The AI governance market is seeing significant growth in highly regulated industries, such as healthcare, finance, and defense, where compliance, safety, and security are critical. In these sectors, the adoption of AI governance frameworks is crucial for ensuring that AI applications meet strict regulatory requirements, and this trend is pushing the demand for specialized governance solutions tailored to industry-specific needs.

A unique feature of the AI governance market is the increasing emphasis on trust and transparency. As AI systems become more pervasive, stakeholders—ranging from end-users to regulators—are demanding clearer explanations of how AI models make decisions. Ensuring that AI systems are interpretable, explainable, and transparent is becoming a core requirement, and this is driving the development of governance solutions that focus on building trust in AI technologies.

Major Highlights of the AI Governance Market

One of the major highlights of the AI governance market is the crucial role that regulatory compliance plays in driving its adoption. As governments and international bodies implement strict regulations surrounding AI, organizations are compelled to establish robust governance frameworks. These frameworks help businesses comply with emerging rules and guidelines related to AI ethics, bias prevention, data privacy, and accountability, ensuring they avoid legal risks and penalties.

Organizations are increasingly aware of the risks associated with AI, such as potential biases, discrimination, and privacy violations. This awareness has spurred significant investment in AI governance tools that help mitigate these risks. Companies are investing in solutions that monitor AI systems to ensure they adhere to ethical standards, perform risk assessments, and enhance accountability, making risk management a critical highlight of the market.

A standout highlight of the AI governance market is its rapid adoption in regulated industries such as healthcare, finance, and insurance. In these sectors, where compliance and risk management are of paramount importance, the need for strong AI governance frameworks is particularly acute.

The demand for trust and transparency in AI operations is another major market highlight. Stakeholders, including customers, employees, and regulators, are increasingly focused on understanding how AI systems make decisions. AI governance solutions that offer greater transparency, explainability, and fairness in AI processes are becoming critical in building trust among users, driving further adoption of governance frameworks across industries.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=176187291

Top Companies in the AI Governance Market

Some leading players in the AI governance market include Microsoft (US), IBM (US), Google (US), Salesforce (US), SAP (Germany), AWS (US), SAS Institute (US), FICO (US), Accenture (Ireland), Qlik (US), H2O.AI (US), Alteryx (US), DataRobot (UK), Dataiku (US), Domino Data Lab (US), SparkCognition (US), Collibra (US), OneTrust (US), Quest Software (US), and Fiddler AI (US). These players have adopted various organic and inorganic growth strategies, such as new product launches, partnerships and collaborations, and mergers and acquisitions, to expand their presence in the AI governance market.

Microsoft

Microsoft has established a robust presence in the AI governance market through its strategic focus on responsible AI. The approach to AI governance from the firm emphasizes openness, fairness, and accountability, which is then fortified by tools such as Microsoft’s AI Responsible Innovation and Azure OpenAI services. Major competencies include embedding AI values into the development of its products, preserving outstanding data security and especially, providing support for achieving AI standards such as the Microsoft Responsible AI Standard. Horizontal integration provides the possibility for buying companies such as Nuance, which would increase the strength of its healthcare AI capability, for example. Liaisons with OpenAI and governments extend its reach while ensuring that it is regulating by worldwide standards. Collaborations and partnerships make sure that its solutions are not only technologically advancing but also aligned with the greatest ethical standards in finance, health care, and public services. These efforts position the company in a good spot regarding dominance in AI governance as both vertical and horizontal strategies build on its impact.

Google

Google has impacted the AI governance field through strategic efforts towards responsible AI development, transparency, and promotion of global policies. One of the major strategies includes partnership with international organizations in ways that call for an ethical governance structure for AI. Through its machine learning, natural language processing, and cloud infrastructure expertise, Google can influence AI governance through the development of robust tools for auditing and AI risk management. Key activities would encompass the establishment of the partnership on AI and launching products such as Google Explainable AI to build transparency. The company is engaging in horizontal integration through the acquisition of AI ethics start-ups and vertical integration through creating governance mechanisms of AI in its core products like Google Cloud and AI-related solutions. In addition, engagement with academic institutions and AI research labs makes it likely to develop standard international standards for AI governance.

IBM

With strategic initiatives like developing watsonx.governance, ensuring its compliance, explainability, and lack of bias, IBM has successfully placed itself in the AI governance market. High competencies include advanced AI technology, data management skills, and industry expertise – all these ability are provided to deliver scalable, sectoral AI solutions. Core activities include governance frameworks development, managing the full lifecycle of AI, and regulatory compliance. IBM invests in joint ventures and partnerships with industry leaders and academic institutions for increased AI governance standards. The company employs vertical integration wherein AI governance is ensured to be embedded with its broader cloud and data-based systems. The same delivers an end-to-end solution to its enterprise clients. A broad approach, therefore, would be the ethical deployment of AI across several industries by strengthening the position of IBM on responsible AI.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103
City: Delray Beach
State: FL 33445
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/ai-governance-market-176187291.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AI Governance Market Growing Trends, Business Growth, Size, Future Scope, Segmentation, Dynamics and Forecast to 2029

Frontotemporal Dementia Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Frontotemporal Dementia Pipeline Insight 2024” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Frontotemporal Dementia Pipeline. Dive into DelveInsight’s comprehensive report today! @ Frontotemporal Dementia Pipeline Outlook

Key Takeaways from the Frontotemporal Dementia Pipeline Report

In October 2024:- Sanofi- To assess prevalence of Gaucher disease (GD) diagnosed in pediatric patients presenting with unexplained splenomegaly (SMG) after exclusion of first intention-diagnoses (e.g. portal hypertension, haematological malignancy, hemolytic anemia, infection) based on clinical examination and routine biological tests (full blood count, reticulocytes, liver tests, abdominal ultrasound, Coombs test and Epstein Barr virus serology).
DelveInsight’s Frontotemporal Dementia pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment.
The leading Frontotemporal Dementia Companies such as Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA., and others
Promising Frontotemporal Dementia Therapies such as LY3884963, DNL593, AL001, PBFT02. Olipudase alfa, and others

Stay ahead with the most recent pipeline outlook for Frontotemporal Dementia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Frontotemporal Dementia Treatment Drugs

Frontotemporal Dementia Emerging Drugs Profile

AL001: Alector

AL001 is a recombinant human anti-human sortilin (SORT1) monoclonal IgG1 developed by Alector in partnership with GSK. It aims to increase the level of progranulin in humans by inhibiting a progranulin degradation mechanism. The antibody received orphan drug designation, fast track designation, and breakthrough designation from the US FDA for the treatment of frontotemporal dementia. Alector Inc. is currently investigating AL001 in Phase III clinical trials for FTD with a C9orf72 mutation and granulin mutation.

TPN-101: Transposon Therapeutics

TPN-101 specifically inhibits the LINE-1 reverse transcriptase that promotes LINE-1 replication. LINE-1 elements are a class of retrotransposable elements that in humans are uniquely capable of replicating and moving to new locations within the genome. When this process becomes dysregulated, LINE-1 reverse transcriptase drives overproduction of LINE-1 DNA, triggering innate immune responses that contribute to neurodegenerative, autoimmune and aging-related disease pathology. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Frontotemporal Dementia.

AVB-101: AviadoBio

AVB-101 is a potential one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels to affected areas of the brain. The drug is delivered using a minimally invasive, stereotactic neurosurgical procedure directly to the part of the brain called the thalamus. The thalamus has extensive connections to other parts of the brain, including the frontal and temporal lobes, which play a critical role in FTD and the symptoms that impact patients and their families. This targeted delivery method aims to safely and effectively cross the blood-brain barrier, delivering targeted treatment directly to the brain to restore progranulin levels in the frontal and temporal cortex where it is needed most, while at the same time minimizing the dose required and thereby limiting any potential systemic exposure. In November 2023, the US Food and Drug Administration (FDA) granted Fast Track designation to AVB-101. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Frontotemporal Dementia.

VES001: Vesper Bio

VES001 is the first oral, brain penetrant, small molecule sortilin inhibitor designed as a potentially disease-modifying treatment for the neuro-cognitive disorder fronto-temporal dementia (FTD (GRN)). Data returned from this study (NCT06226064) demonstrate the safety and tolerability of VES001 across the full range of doses tested and show it has excellent pharmacokinetics and distribution to relevant parts of the brain. The data predict a once or twice daily efficacious dose. Importantly, volunteers who received VES001 experienced significant and robust increases in levels of progranulin, demonstrating target engagement. Progranulin is a protein known to play a key role in promoting neuron survival, growth and function. People with FTD(GRN) have inherited gene mutations associated with low progranulin levels.

Explore groundbreaking therapies and clinical trials in the Frontotemporal Dementia Pipeline. Access DelveInsight’s detailed report now! @ New Frontotemporal Dementia Drugs

Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Frontotemporal Dementia Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Unveil the future of Frontotemporal Dementia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Frontotemporal Dementia Market Drivers and Barriers

Scope of the Frontotemporal Dementia Pipeline Report

Coverage- Global
Frontotemporal Dementia Companies- Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA., and others.
Frontotemporal Dementia Therapies- LY3884963, DNL593, AL001, PBFT02. Olipudase alfa, and others
Frontotemporal Dementia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Frontotemporal Dementia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Frontotemporal Dementia Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Frontotemporal Dementia Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Frontotemporal Dementia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Frontotemporal Dementia– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Latozinemab: Alector
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
PR 006 : Prevail Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
EXO-050: Coya Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Frontotemporal Dementia Key Companies
Frontotemporal Dementia Key Products
Frontotemporal Dementia- Unmet Needs
Frontotemporal Dementia- Market Drivers and Barriers
Frontotemporal Dementia- Future Perspectives and Conclusion
Frontotemporal Dementia Analyst Views
Frontotemporal Dementia Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Frontotemporal Dementia Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Veterinary Vaccines Market Trends, Key Players Analysis, Regional Trends, Competitive Landscape, and Industry Potential by 2027

“The major players in the veterinary vaccines market include Zoetis, Inc. (US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health (US), Virbac (France).”

The future of the veterinary vaccines industry looks promising. The industry is expected to grow at a steady rate over the next few years, driven by rising demand for pet health products and increasing awareness of pet health among pet owners.

Veterinary Vaccines Market in terms of revenue was estimated to be worth $8.1 billion in 2022 and is poised to reach $10.8 billion by 2027, growing at a CAGR of 5.9% from 2022 to 2027 according to a new report by MarketsandMarkets™. Growth in this market can primarily be attributed to the growing demand for pet insurance and rising animal health expenditure. Spending on pet healthcare—which includes the purchase of pet food, supplies/over-the-counter medications, veterinary care, pet insurance policies, and other services, has increased significantly in recent years. A large number of pet owners, especially in major markets across North America and Europe, are purchasing pet insurance because of the significant growth in pet care expenditure in recent years.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1233

Injectable vaccines accounted for the largest share of the veterinary vaccines market

Based on the route of administration, the veterinary vaccines market is segmented into injectable vaccines, oral vaccines, and intranasal/spray vaccines. In 2021, injectable vaccines accounted for the largest share of the veterinary vaccines market. This mode of administration allows the medication to be absorbed into the bloodstream quickly. It also results in a better immune response and a lower rate of injection-site reactions, this factor will support the market growth.

The veterinary hospitals segment accounted for the largest share of the veterinary vaccines market

Based on the distribution channel, the veterinary vaccines market is segmented into veterinary hospitals, veterinary clinics, and retail pharmacies. In 2021, the veterinary hospitals segment accounted for the largest share of the veterinary vaccines market. The large share of the veterinary hospitals segment is attributed to the growing awareness about animal health in developing countries.

Asia Pacific segment accounted for the largest share of the veterinary vaccines market

The global veterinary vaccines market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, Asia Pacific segment accounted for the largest share of the veterinary vaccines market. The growing trend of pet ownership in APAC countries has resulted in increased pet healthcare expenditures. This can also be attributed to the growing disposable income levels in APAC countries, due to which the willingness to spend on animal healthcare and well-being is rising.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=1233

Veterinary Vaccines Market Dynamics:

Drivers:

1. Growth in companion animal population

2. Rising incidence of zoonotic diseases

3. Initiatives by various government agencies and animal associations

4. Rising demand for animal-derived food products

5. Growing demand for pet insurance and rising animal health expenditure

Restraints:

1. High storage cost of vaccines

2. Rising pet care costs

Opportunities:

1. Technological advancements

2. Untapped emerging markets

Challenges:

1. Inadequate surveillance and reporting systems

2. Lack of animal healthcare awareness in emerging countries

Key Market Players:

The major players in the veterinary vaccines market include Zoetis, Inc. (US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health (US), Virbac (France).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=1233

Recent Developments:

In September 2022, Zoetis acquired Jurox, a privately held animal health company that develops, manufactures, and markets a wide range of veterinary medicines for treating livestock and companion animals.
In June 2022, Boehringer Ingelheim and CarthroniX partnered to pursue small molecule therapeutics in canine oncology.
In July 2021, Elanco acquired KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics.

Veterinary Vaccines Market Advantages:

Veterinary vaccines are important for the prevention of animal diseases and the reduction of animal deaths.
Vaccines can help reduce the spread of zoonotic diseases from animals to humans, thus reducing the risk of human disease.
Veterinary vaccines can prevent the transfer of disease between animals, which can help to improve the health and productivity of livestock herds, and reduce the economic losses associated with animal diseases.
Vaccination can also help to reduce the use of antibiotics, which can help to reduce the emergence of antibiotic-resistant bacteria.
Veterinary vaccines can help to reduce the spread of emerging diseases and pandemics, which can cause serious economic and public health consequences.
Veterinary vaccines are relatively inexpensive and easy to administer, making them accessible to a wide range of veterinary practices.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Veterinary Vaccines Market Trends, Key Players Analysis, Regional Trends, Competitive Landscape, and Industry Potential by 2027

Metastatic Colorectal Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Metastatic Colorectal Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Metastatic Colorectal Cancer Pipeline Outlook

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report

In October 2024:- Buzzard Pharmaceuticals- A Phase IIa, Non-Randomized, Open-Label Dose Expansion Trial of Isunakinra in Combination with Pembrolizumab in Patients with Metastatic or Unresectable, Locally Advanced Colorectal Cancer. In this study the investoigators are testing a new type of immunotherapy aclled isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this otherwise effective treatment to work on this treatment resistant type of tumor.
In October 2024:- AbbVie- An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer.
DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Metastatic Colorectal Cancer treatment.
The leading Metastatic Colorectal Cancer Companies such as Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech, and others.
Promising Metastatic Colorectal Cancer Therapies such as Encorafenib, Cetuximab, NPX267, MRTX849, Cetuximab, TNO155, BXQ-350, and others

Stay ahead with the most recent pipeline outlook for Metastatic Colorectal Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Colorectal Cancer Treatment Drugs

Metastatic Colorectal Cancer Emerging Drugs Profile

Lumakras (sotorasib): Amgen

Lumakras (sotorasib) is a highly selective inhibitor of KRAS G12C that potentially suppresses the rapid proliferation of cancer cells. Sotorasib forms an irreversible, covalent bond with the cysteine residue of KRAS G12C, holding the protein in its inactive form that blocks the oncogenic signaling. This results in apoptosis only in KRAS G12C tumor cell. It is being investigated as a treatment for a variety of solid tumors, including NSCLC, colorectal cancer and other solid tumor cancers. Currently, the drug is in the Phase III stage of its development for the treatment of Metastatic Colorectal Cancer.

Axitinib: Pfizer

Axitinib is an oral therapy that is designed to inhibit tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3; these receptors can influence tumor growth, vascular angiogenesis and progression of cancer. In the U.S., INLYTA is approved for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. Currently, the drug is in the Phase II stage of its development for the treatment of Metastatic Colorectal Cancer.

NX 1607: Nurix Therapeutics Inc

NX-1607 is an orally bioavailable inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B) for immuno-oncology indications, including a range of solid tumor types. NX-1607 acts on T cells, NK cells, and dendritic cells to enhance anti-tumor immunity, and has demonstrated single-agent anti-tumor activity in multiple tumor models. Nurix is evaluating NX-1607 in an ongoing, Phase I dose escalation and expansion trial in adults with a variety of oncology indications at multiple clinical sites. Currently, the drug is in the Phase I stage of its development for the treatment of Metastatic Colorectal Cancer.

TP-1454: Sumitomo Dainippon Pharma Oncology

TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator that is currently being evaluated in a Phase I/I b study in patients with advanced metastatic or progressive solid tumors. TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment. Currently, the drug is in the Phase I stage of its development for the treatment of Metastatic Colorectal Cancer.

Explore groundbreaking therapies and clinical trials in the Metastatic Colorectal Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Metastatic Colorectal Cancer Drugs

Metastatic colorectal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Parenteral
Intravenous
Subcutaneous
Topical.

Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Unveil the future of Metastatic Colorectal Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Metastatic Colorectal Cancer Market Drivers and Barriers

Scope of the Metastatic Colorectal Cancer Pipeline Report

Coverage- Global
Metastatic Colorectal Cancer Companies- Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech, and others.
Metastatic Colorectal Cancer Therapies- Encorafenib, Cetuximab, NPX267, MRTX849, Cetuximab, TNO155, BXQ-350, and others.
Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Metastatic Colorectal Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Metastatic Colorectal Cancer Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Metastatic colorectal cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Metastatic colorectal cancer Collaboration Deals
Late Stage Products (Phase III)
Lumakras (sotorasib): Amgen
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Axitinib: Pfizer
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
NX 1607: Nurix Therapeutics Inc
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Metastatic colorectal cancer Key Companies
Metastatic colorectal cancer Key Products
Metastatic colorectal cancer- Unmet Needs
Metastatic colorectal cancer- Market Drivers and Barriers
Metastatic colorectal cancer- Future Perspectives and Conclusion
Metastatic Colorectal Cancer Analyst Views
Metastatic Colorectal Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Colorectal Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

E-Commerce Market is Forecasted to Expand at a Stellar 11% CAGR through 2031, Rising Disposable Income Projected to Create New Opportunities for Market Growth

E-Commerce Market size was valued at USD 24029.23 billion in 2022 and is poised to grow from USD 26673.64 billion in 2023 to USD 62415.2 billion by 2031, growing at a CAGR of 11% in the forecast period (2024-2031).

Rapidly increasing internet penetration and evolving consumer preferences are projected to be key factors promoting the demand for e-commerce around the world. Increasing digitization of the retail industry is also expected to favour the demand for e-commerce platforms over the coming years. Moreover, an increasing number of e-commerce companies around the world are also expected to create new business opportunities going forward.

E-commerce companies should focus on expanding their business scope through the launch of new services and products. With the presence of key names such as Alibaba and Amazon in this industry, the competition is quite tough. However, innovative marketing and attractive discounts and offers are expected to play a crucial role in creating new opportunities for incoming e-commerce companies. Developing and underdeveloped countries are forecasted to be the most opportune markets for e-commerce companies in the long run as disposable income of people is increasing.

Download a detailed overview:

https://www.skyquestt.com/sample-request/e-commerce-market

Launching New Products to Stay Competitive – Key Strategy for e-Commerce Providers

e-Commerce companies should focus on collaborations and partnerships to expand their business scope and offer more products and services. Providing great discounts will also be a key focus of many e-commerce companies looking to increase their revenue generation potential in the future. Integration of advanced payment options and providing buy now pay later services will also help e-commerce companies expand their revenue generation potential in the long run. Quick commerce is also a key trend that e-commerce companies can capitalize on going forward.

In February 2024, Energy Efficiency Services Limited (EESL) an Indian state-owned organization announced the launch of its new e-commerce platform in its beta version. The company intends to maximize its sales and offer customers affordable energy products to its users through this new move.
In August 2024, Chanel, a renowned fashion house based out of the United Kingdom announced the launch of its e-commerce platform in India. Chanel’s fragrance, beauty and eyewear offerings were made available to the Indian consumers via this platform launch and intended to capitalize on the e-commerce boom in the country.
In October 2024, Kerala State Beverages Corporation (BEVCO) revealed its plans of launching a new e-commerce application for liquor sales. The application will not allow home delivery of liquor but allow users to choose a pickup time and location. The move is intended to reduce queues at liquor stores and modernize the liquor industry as well.
In August 2024, Seagate Technology plc., a renowned provider of storage solutions announced the launch of its new e-commerce website in Canada to provide better shopping experience for its customers. This launch came after a successful one in the United States previously this year.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/e-commerce-market

This report covers the following segments:

A. Business Model
Vertical e-commerce
Horizontal e-commerce
B. Product Offering
Home Appliances
Apparel, Footwear
Accessories
Books
Beauty & Cosmetics
Groceries
Others
C. Browsing Medium
Desktop/Laptop
Mobile/Tablet
D. Business Transaction
Business-to-Business
Business-to-Consumer
Consumer-to-Consumer

This report covers the following players:

Amazon.com Inc.
Alibaba Group Holding Limited
Walmart Inc.
JD.com Inc.
eBay Inc.
Rakuten Inc.
Zalando SE
Shopify Inc.
MercadoLibre Inc.
Etsy Inc.
Pinduoduo Inc.
Flipkart Internet Private Limited
Wayfair Inc.
Otto GmbH & Co KG
Groupon Inc.
Vipshop Holdings Limited
Overstock.com Inc.
ASOS Plc
Qurate Retail Group, Inc.
Chewy, Inc.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/e-commerce-market

Standing out in the e-commerce business could be a tough feat to achieve. Choosing the right strategies and markets will be crucial in determining the success of any e-commerce company going forward. Targeting domestic and local markets should be a priority for new as well as established e-commerce companies across the study period and beyond.

About Us:

SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.

We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific.

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/e-commerce-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: E-Commerce Market is Forecasted to Expand at a Stellar 11% CAGR through 2031, Rising Disposable Income Projected to Create New Opportunities for Market Growth

Lil Prince Charmin’s Highly Anticipated New Single “STR8 OUTTA CANDY” Now Available Worldwide

Lil Prince Charmin has just released his highly anticipated new single “STR8 OUTTA CANDY” worldwide.

Lil Prince Charmin’ has been charming his way into the hearts of all generations since the age of 4 years old when he began doing Covers of the King of Soul James Brown until he later turned his focus to the King of Pop Michael Jackson. He has since been Rockin’ stages all over the globe since age 6 with a plethora of New Orleans talent including: Tucka King of Swing, Rockin’ Dopsie Jr., Dwayne Dopsie, Gina Brown, Hot Boy Ronald, Rob49, and T99zy. Lil’ Prince was even invited as a featured performer at the James Brown Birthday Bash in Augusta Ga. by Mr. Bootsy Collins.

Lil Prince Charmin opened for Tamar Braxton and Boosie Badazz at the Westbank Heritage Festival as well as teaming up with DJ Spin, Alvin Juggie McMillan Jr, Partners-N-Crime, DJ Jubilee, and Baby Boy da Prince for the Friends of Choppa Showcase in honor of Choppa Style at Nola’s Fried Chicken Festival.

Now at age 12, Lil Prince Charmin’ is a producer, recording artist writing his own rhymes and music, musical animation creator, and phenomenal live entertainer on a mission to becoming known as the positive vibe so desperately needed for our youth… And proving that chivalry is back! He cares, he dares and he shares his out of the box creativity and talent in an overwhelmingly dedicated fashion with a tapestry of songs that keeps you moving’.

His recently released single “I Like It When She Go (Bop)” has hit sound-waves all the way to Africa. His sound celebrates a whole lot of soul and a marathon of pop seasoned with spicy Nola Bounce. His energy is endless like that of a raging tsunami, and his style is that of fireworks plunging into the night sky and lighting up the darkness.

Lil Prince Charmin’ is bringing love and unity to the world through his positive music and dance. Get ready for “The Real Life Prince Charmin Experience”, New Orleans very own…

Download or stream Lil Prince Charmin’s “STR8 OUTTA CANDY” here:

https://distrokid.com/hyperfollow/lilprincecharmin/str8-outta-candy

Follow Lil Prince Charmin on IG https://www.instagram.com/lilprincecharmin/

Media Contact
Company Name: World Star PR
Contact Person: Jimmy Star
Email: Send Email
Phone: 631-506-6600
Country: United States
Website: https://www.facebook.com/WorldStarPR/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lil Prince Charmin’s Highly Anticipated New Single “STR8 OUTTA CANDY” Now Available Worldwide

FEP Heat Shrink Medical Tubing Market 2024; Top Business Strategy, Industry Growth Factors, Healthy CAGR with Industry Segments & Review

“Browse 337 market data Tables and 44 Figures spread through 258 Pages and in-depth TOC on “FEP Heat Shrink Medical Tubing Market”

The demand for FEP heat shrink medical tubing is anticipated to grow steadily, driven by the increasing adoption of advanced medical devices and the need for reliable, high-performance tubing solutions in critical healthcare applications. As the healthcare sector continues to innovate, FEP heat shrink tubing’s unique properties

The FEP heat shrink medical tubing market size is estimated to be USD 145 million in 2024, and it is projected to reach USD 208 million by 2029 at a CAGR of 7.4%. The global FEP heat shrink medical tubing industry is undergoing significant growth, driven by its wide range applications. Most manufacturers in this market are based in North America and Asia Pacific. Zeus Company LLC (US), TE Connectivity Limited (Switzerland), Parker-Hannifin Corporation (US), Teleflex Incorporated (US), and Junkosha Inc. (Japan) are among the leading players operating in the FEP heat shrink medical tubing market. These players have adopted various growth strategies to strengthen their position in the market. This includes expansions and acquisition activities further to expand their presence in the FEP heat shrink medical tubing market.

FEP Heat Shrink Medical Tubing Companies

Zeus Company LLC (US)

Zeus Company LLC, a global producer of advanced polymer solutions, was officially acquired by EQT in February 2024. The company specializes in manufacturing a wide range of products, including heat shrinkable tubing, extruded tubing, reinforced optical fiber, biomaterials, insulated wire, monofilament and drawn fiber, tie layer, and more. Serving diverse markets such as aerospace, medical, automotive, energy, fiber optics, and fluid management, Zeus operates manufacturing and sales facilities across three continents, with a presence in 180 countries worldwide. Boasting 10 world-class facilities globally, Zeus is renowned for its exceptional products and services in the medical industry. The company offers heat shrink tubing in various polymer resins, including PTFE, FEP, PFA, ETFE, PEEK, and PTFE/FEP dual link. Zeus provides FEP shrink tubing with three different shrink ratios: 1.3:1, 1.6:1, and 2:1. Supplying high-performance polymer heat shrink to numerous industries, including medical, electronics, aerospace, automotive, oil, gas, and more, Zeus continues to be a leading provider of innovative solutions worldwide.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=88280405

TE Connectivity (Switzerland)

TE Connectivity is a leading global provider of industrial technology solutions, specializing in the design and production of connectivity and sensor solutions. The company caters to various industries, including medical technology, transportation, industrial applications, and data communications. Operating through segments like Transportation Solutions, Industrial Solutions, and Communications Solutions, TE Connectivity offers a diverse range of products and services. In the Industrial Solutions segment, the company offers essential solutions such as heat shrink tubing, terminal and connector systems, relays, wire and cable, among others. Under the brand name “RAYCHEM,” TE Connectivity provides heat shrink tubing in three variants: dual wall tubing, orange heat shrink tubing, and single wall tubing. The company offers medical grade heat shrink tubing under the series name “RAYCHEM MT-FEP.” With over 100 manufacturing sites worldwide, TE Connectivity serves customers across 140 countries, reinforcing its position as a global leader in industrial technology solutions.

Parker-Hannifin Corporation (US)

Parker-Hannifin Corporation stands as a prominent global manufacturer of diversified motion and control technologies and systems. With a commitment to precision engineering, the company delivers tailored solutions across various markets. These include aerospace, healthcare & life sciences, electronics & semiconductors, transportation, oil & gas, among others. Operating in 45 countries worldwide, Parker-Hannifin’s manufacturing, service, sales, distribution, and administrative facilities span 39 states in the US and in 43 other countries. Structured into two segments, diversified industrial and aerospace systems, the company’s extensive product portfolio encompasses adhesives, coatings, encapsulants, hose, piping, tubing, EMI shielding, gas generators, pumps, cylinders, actuators, and more. Among its offerings are FEP, ETFE, and PTFE heat shrink tubing solutions.

Get Sample Copy of this Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=88280405

Teleflex Incorporated (US)

Teleflex Incorporated is a renowned global supplier of medical technology solutions, specializing in the design, development, manufacturing, and distribution of single-use medical devices for hospitals and healthcare providers. These devices are crucial for various diagnostic and therapeutic procedures in critical care and surgical applications. With major manufacturing operations in the Czech Republic, Malaysia, Mexico, and the US, Teleflex operates through four regional segments: Americas, EMEA (Europe, the Middle East, and Africa), Asia (Asia Pacific), and OEM (Original Equipment Manufacturer and Development Services). Each geographic segment offers an extensive range of medical technology products tailored to the needs of hospitals and healthcare providers. Teleflex’s product categories encompass vascular access, anesthesia, interventional, surgical, interventional urology, respiratory, and urology. Serving hospitals and healthcare providers, medical device manufacturers, and home care sectors, Teleflex is dedicated to enhancing patient care worldwide. Under the Teleflex Medical OEM division, the company provides FEP heat shrink tubing solutions.

Junkosha Inc. (Japan)

Junkosha Inc. is the world’s first melt-processable fluoropolymer molding manufacturer. Specializing in the production and distribution of high-performance polymer products, including wires, cables, tubing, connectors, and injection moldings primarily made from fluoropolymers, the company caters to diverse markets such as medical, aerospace, transportation, and others. With operations spanning eight locations across the US, Europe, China, and Japan, Junkosha collaborates with approximately 1,500 companies across 32 countries and regions. All of its products are carefully designed and manufactured in Japan, adhering to strict standards. The company has over 160 granted patents, underscoring its commitment to innovation and excellence.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=88280405

By Shrink Ratio, 1.6:1 accounted for the largest share in 2023.

1.6:1 offers a moderate level of shrinkage, allowing the tubing to fit snugly around medical device components without excessive compression. This versatility makes it suitable for a wide range of medical devices, including catheters, guide wires, and stent delivery systems. Additionally, the 1.6:1 ratio provides precise control over the final dimensions of the tubing, ensuring tight tolerances necessary for proper device functionality. Its flexibility, compatibility with different materials, and cost-effectiveness further contribute to its widespread adoption in the healthcare industry.

By Product Type, Standard FEP HS Tubing accounted for the largest share in 2023.

Standard FEP heat shrink tubing offers excellent properties such as high temperature resistance, chemical inertness, flexibility, and transparency. These characteristics make it suitable for various medical device applications, including catheters, guide wires, and stent delivery systems. Its versatility allows for easy customization to meet specific size and performance requirements.

North America is the largest market for the FEP Heat Shrink Medical Tubing market.

The North America region is accounted to be the largest market both in terms of value and volume in 2023. The region is home to a large number of leading medical device manufacturers and research institutions, driving innovation and demand for advanced medical tubing solutions. Additionally, North America has a well-established healthcare infrastructure and high healthcare expenditure, which supports the adoption of FEP heat shrink medical tubing in various medical applications.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/fep-heat-shrink-medical-tubing-market-88280405.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: FEP Heat Shrink Medical Tubing Market 2024; Top Business Strategy, Industry Growth Factors, Healthy CAGR with Industry Segments & Review

The Boulder Group Arranges Sale of Net Leased Fast Pace Health Property in Tennessee

Randy Blankstein and Jimmy Goodman of The Boulder Group represented the seller in the transaction.

The Boulder Group, a net leased investment brokerage firm completed the sale of a single tenant Fast Pace Health located at 3082 Kirby Whitten Road in Bartlett, Tennessee for $2,696,296.

The 3,700 square foot Fast Pace facility benefits from its position along Kirby Whitten Road which experiences 28,300+ vehicles per day. The property is placed in a large cluster of nationally recognized retailers including Kroger, ALDI, Goodwill, Chick-Fil-A, Starbucks, Walgreens, Five Guys, McAlister’s Deli, AutoZone, Valvoline, Taco Bell, and several others. All of which drive a continual pattern of traffic through the corridor. There are over 167,500 people living within a 5-mile radius of Fast Pace. The average household income of the 5-mile population is $88,046. Furthermore, the property is less than 10 minutes west of Saint Francis Hospital-Bartlett, a 156-Bed full service medical facility.

Randy Blankstein and Jimmy Goodman of The Boulder Group represented the seller in the transaction. The seller was a private real estate investor, and the buyer was in a 1031 exchange.

There are over 14 years remaining on the primary lease term. Construction was completed in late 2023. Fast Pace operates 235+ healthcare centers across Tennessee, Kentucky, Louisiana, Mississippi, and Indiana. Each Fast Pace clinic features multiple exam rooms, on-site lab testing, and x-ray capabilities.

“New construction properties with long term leases to e-commerce resistant tenants are the most sought-after net lease product,” said Randy Blankstein, President of The Boulder Group. Jimmy Goodman of The Boulder Group, added, “Net lease transactions continue garner significant interest in tax-free states such as Tennessee.”

About The Boulder Group

The Boulder Group is a boutique investment real estate service firm specializing in single tenant net lease properties. The firm provides a full range of brokerage, advisory, and financing services nationwide to a substantial and diversified client base, which includes high-net-worth individuals, developers, REITs, partnerships and institutional investment funds. Founded in 1997, the firm has arranged the acquisition and disposition of over $9 billion of single tenant net lease real estate transactions. From 2013-2023, the firm was ranked in the top 10 companies in the nation for single tenant retail transactions by both Real Capital Analytics and CoStar. The Boulder Group is headquartered in suburban Chicago and has an office in Denver.

More info: www.bouldergroup.com

Media Contact
Company Name: The Boulder Group
Contact Person: Randy Blankstein
Email: Send Email
Phone: 8478816388
Address:3520 Lake Avenue Suite 203
City: Wilmette
State: Illinois
Country: United States
Website: https://www.bouldergroup.com/NNN-Properties-For-Sale.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Boulder Group Arranges Sale of Net Leased Fast Pace Health Property in Tennessee